Second, since the vast majority of SETD7 function involves non-histone protein methylation, the quantitative profiling of SETD7 targets using mass spectrometry and enrichment for lysine methylation in different cancer models (in vivo and in vitro) and in various cellular contexts (hypoxia, genotoxic stress, etc.), is a pressing need in the field. The gene discussed is SETD7; the disease is cancer.